natgillin/translations-raw huggingface dataset:
The method of claim 1, further comprising administering to the patient one or more additional therapeutic agent(s) selected from the group consisting of an IL-1 inhibitor, an IL-18 inhibitor, an IL-4 inhibitor, an IL-4 receptor inhibitor, an IL-6 inhibitor, an IL-6 receptor inhibitor, a nerve growth factor (NGF) inhibitor, a tumor necrosis factor (TNF) inhibitor, a TNF receptor inhibitor, a uric acid synthesis inhibitor and a corticosteroid. 
Izolirano antitijelo, antigen vezujući fragment ili pripravak prema zahtjevu 9, za primjenu prema zahtjevu 9, pri čemu se način dodatno sastoji od davanja bolesniku najmanje jednog dodatnog terapijski aktivnog sastojka odabranog iz grupe koja se sastoji od inhibitora IL-1, inhibitora IL-18, inhibitora IL-4, inhibitora receptora IL-4, inhibitora IL-6, inhibitora receptora IL-6, inhibitora nervnog faktora rasta (NGF), inhibitora faktora nekroze tumora (TNF) i inhibitora receptora TNF-a, inhibitora sinteze mokraćne kiseline i kortikosteroida.
The composition of claim 17, wherein the cationic lipid is 5 to 4mol % of the lipid molecules. 
Pripravak u skladu s patentnim zahtjevom 8, naznačen time što je kationski lipid 5 do 40 mol % molekula lipida.
optionally where the cancer is selected from breast cancer, ovarian cancer, tumors of the endometrium, cervical carcinoma, lung cancer, prostate cancer, pancreatic cancer, hematological cancers, leukemias, colon cancer, bowel tumors, glioblastomas, lymphomas, and melanomas; and 
Spoj ili pripravak za primjenu prema zahtjevu 12, naznačen time, što je rak odabran iz skupine koja se sastoji od raka dojke, raka jajnika, tumora endometrija, karcinoma vrata maternice, raka pluća, raka prostate, raka gušterače, hematološkog karcinoma, leukemije, raka debelog crijeva, tumora crijeva, glioblastoma, limfoma i melanoma.
for compounds of formula I in which there is a Q1 to Q6 substituent present, in which such groups represent -OR10a or -OR20, as appropriate, in which R10a and R20 do not represent hydrogen, reaction of a corresponding compound of formula I in which there is a Q1 to Q6 present, which represents -OR10a and -OR20 (as appropriate), in which R10a and R20 do represent hydrogen, with a compound of formula VI, Rx-L5 VI wherein L5 represents a suitable leaving group and Rx represents R10a or R20 (as appropriate), provided that it does not represent hydrogen. 
za spojeve s formulom I u kojoj, kako je prikladno, postoji prisutan supstituent Q1 do Q6, u kojoj takve skupine predstavljaju -OR10a ili -OR20, u kojoj R10a i R20 ne predstavljaju vodik, reakciju odgovarajućeg spoja formule I u kojoj postoji prisutan Q1 do Q6, koji predstavlja -OR10a i -OR20 (kako je prikladno), u kojoj R10a i R20 do predstavljaju vodik, sa spojem s formulom VI, Rx-L5 VI pri čemu L5 predstavlja prikladnu izlaznu skupinu i Rx predstavlja R10a ili R20 (kako je prikladno), pod uvjetom da ne predstavljaju vodik.
The compounds of the present invention can therefore be used as pharmaceutical agents for preventing weight gain, promoting weight loss, reducing excess body weight or treating obesity (e.g. by control of appetite, feeding, food intake, calorie intake, and/or energy expenditure), including morbid obesity, as well as associated diseases and health conditions including but not limited to obesity linked inflammation, obesity linked gallbladder disease and obesity induced sleep apnea. The compounds of the invention may also be used for treatment of insulin resistance, glucose intolerance, pre-diabetes, increased fasting glucose, type 2 diabetes, hypertension, dyslipidemia (or a combination of these metabolic risk factors), atherosclerois, arteriosclerosis, coronary heart disease, peripheral artery disease and stroke. 
(b) poboljšanje razina glukoze u cirkulaciji, tolerancije na glukozu i/ili cirkulacijskih razina kolesterola, snižavanje cirkulacijskih razina LDL, i/ili povećanje omjera HDL/LDL, kod pojedinca kojemu je to potrebno; ili (c) liječenje stanja uzrokovanih ili karakteriziranih s viškom tjelesne težine, dok je to liječenje 1/ili prevencija za sljedeće: pretilost, morbidna pretilost, upala povezana s pretilosti, bolest žučnog mjehura povezana s pretilosti, apneja u spavanju uzrokovana s pretilosti, metabolički sindrom, pred-dijabetes, otpornost na inzulin, netolerancija na glukozu, dijabetes tipa II, dijabetes tipa I, hipertenzija, aterogena dislipidemija, ateroskleroza, arterioskleroza, koronarna srčana bolest, bolest periferne arterije, udar ili mikrovaskularna bolest, kod pojedinca kojemu je to potrebno.
Use according to claim 2, wherein the metal oxide is selected from the group consisting of CeO2, HfO2, WO3 and PdO and the biocompatible coating is sodium hexametaphosphate (HMP). 
Uporaba prema zahtjevu 2, gdje se metalni oksid odabire 12 skupine koju čine CeO,, HfO,, WO; i PdO i biorazgradiva ovojnica je natrijev heksametafosfat (HMP).
Heteromolecular metal complexes (chelates) disclosed in claim 1 or 2, wherein molecule A is a totally or partially sulfonated humic acid. 
Heteromolekularni metalni kompleksi (kelati) otkriveni u zahtjevima 1 do 7, naznačeni time što je molekula A u cijelosti ili djelomično sulfonirana huminska kiselina.
In the Korean patent application No. 
02.06.2008. Broj europske prijave patenta:
The reaction mixture was filtered and evaporated, and re-dissolved in ethyl acetate (100 mL) and NaHCO3 (sat., 60 mL). 
Reakcijska smjesa se filtrira i upari, te ponovno otopi u etil acetatu (100 ml) i NaHCO, (zas., 60 ml).
The method of claim 7, wherein the POE sorbitan is selected from the group consisting of POE sorbitan 10, POE sorbitan 20, POE sorbitan 40, and POE sorbitan 80. 
Predmetni pripravak prema patentnom zahtjevu 1, naznačen time, da je spomenuti POE sorbitan odabran iz skupine koja se sastoji od POE sorbitana 10, POE sorbitana 20, POE sorbitana 40 te POE sorbitana 80.
The composition or vaccine of any one of claims 1-11 for use in a method of inducing a protective response in an animal comprising at least one administration of the composition or vaccine. 
Pripravak ili cjepivo prema patentnom zahtjevu 1 ili zahtjevu 2, naznačen/o time, da se upotrebljava u postupku induciranja zaštitne reakcije kod životinje, protiv virusa Newcastleske bolesti (NDV), virusa infektivnog bursitisa (primjerice IBDV ili virusa Gumboro-bolesti), virusa Marekove bolesti (engl.
The compound of claim 2, characterized by one or more of the following features: 
Spoj iz zahtjeva 1, naznačen time, što ima jednu ili više od slijedećih osobina:
it has an improved homogeneity compared to at least one protein molecule composition of the same protein molecule when expressed in the cell line CHOdhfr− [ATCC No. 
- ima poboljšanu homogenost u usporedbi s pripravkom s najmanje jednom molekulom protutijela za istu molekulu protutijela kada se eksprimira u staničnoj liniji ATCC No.
said adjunct compound is selected from phenothiazines, substituted benzamides, antihistamines, butyrophenones, corticosteroids, benzodiazepines, cannabinoids, zoledronic acid, pamidronic acid, erythropoietin, G-CSF, filgrastim, lenograstim, darbepoetin other anti-emetics, other serotonin antagonists, other bisphosphonates or other hematopoietic growth factors; 
Oblik prema zahtjevu 33 ili 34, gdje se dodatni spoj izabire između fenotiazina, supstituiranih benzamida, antihistamina, butirofenona, kortikosteroida, benzodiazepina, kanabinoida, zoledronične kiseline, pamidronične kiseline, eritropoetina, G-CSF, filgrastima, lenograstima, darbepoetina, drugih anti-emetika, drugih antagonista serotonina, drugih bisfosfonata ili drugih hematopoetskih faktora rasta.
The process of claim 1, further comprising producing a compound of formula 7 by reacting a compound of Formula 6 with a reagent capable of causing a protecting group to be attached to the phenolic oxygen of a compound of Formula 6 in the presence of a solvent. 
R2 Formula 6 s reagensom koji može uzrokovati da se zaštitna skupina veže za fenolni kisik spoja koji s formulom 6 u prisutnosti otapala.
The method according to claim 29, wherein said extensions, which are wide enough to reach the end of the membrane flap, must allow sealing, and are heat-sealing tapes or meshes made of synthetic material, mesh fabrics, weaved fabrics or three-dimensional fabrics, through which sealing materials, comprising silicone or polyurethane adhesives, can pass, and the membrane must be applied after the coupling of said elements so as to waterproof the connecting point among the different materials. 
Postupak u skladu s jednim ili više od prethodnih patentnih zahtjeva, naznačen time, da navedeni produžeci (28), koji su dovoljno široki da dosegnu kraj preklopnice membrane, moraju osigurati brtveno spajanje, a to su termoljepljive vrpce ili mrežice izrađene od sintetičkih materijala, mrežaste tkanine, tkane tkanine, trodimenzionalne tkanine ili slični materijali kroz koje mogu proći materijali za brtveno spajanje, poput silikonskih ili pohuretanskih ljepila 1 membrana (13), moraju se nanijeti nakon spajanja navedenih elemenata tako da spojevi između različitih materijala postanu vodonepropusni.
Examples of cancer to be treated herein include, but are not limited to, B cell proliferative disorder is selected from lymphoma, non-Hodgkins lymphoma (NHL), aggressive NHL, relapsed aggressive NHL, relapsed indolent NHL, refractory NHL, refractory indolent NHL, chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma, leukemia, hairy cell leukemia (HCL), acute lymphocytic leukemia (ALL), and mantle cell lymphoma. 
Farmaceutski sastav prema zahtjevu 16 za uporabu prema zahtjevu 17, naznačen time, da je proliferativni poremećaj B-stanice odabran od sljedećih: limfom, non-Hodgkinov limfom (NHL), agresivni NHL, recidivni agresivni NHL, recidivni indolentni NHL, otporan NHL, otporan indolentni NHL, kronična limfocitna leukemija (CLL), mali limfocitni limfom, leukemija, leukemija kosmatih stanica (HCL), akutna limfocitna leukemija (ALI), limfom plaštenih stanica.
Use according to claim 1, characterized in that said at least one disintegrant is cross-linked sodium carboxymethylcellulose. 
Upotreba u skladu s patentnim zahtjevom 1, naznačena time što navedeno najmanje jedno sredstvo za raspadanje je umrežena natrij-karboksimetilceluloza.
wherein Y is defined above; to obtain a compound of formula IVb in the form of diastereomeric mixture (R,S+S,S) wherein Y is defined above; 
file u kojoj je Y, kako je definirano u zahtjevu 1; da bi se dobio spoj formule IVb u obliku dijasteroizomerne smjese (R, S+S, S) p)
the message having content (C) and as applied in step B; 
- < sadržaju (C) iz poruke primljene u koraku B;
A foil strip 50 is located on the inside of the paper, toward the fuel end of the article. 
Vrpca 50 od folije nalazi se na unutrašnjosti papira, prema gorivom kraju proizvoda.
(0-2″) reacting the compound of formula II″ with a compound of formula III 
(0-2) redukcija nitro-skupine od spoja formule I' u svrhu dobivanja spoja formule I'' dj" i
In a variation, for the catalyst of step a) or b), the quantity of metal from group VIB is in the range 5% to 40% by weight of oxide of the metal from group VIB with respect to the total catalyst weight, the quantity of metal from group VIII is in the range 1% to 10% by weight of oxide of the metal from group VIII with respect to the total catalyst weight, and the quantity of phosphorus is in the range 0.1% to 10% by weight of P2O5 with respect to the total catalyst weight. 
Postupak prema zahtjevu 1 ili zahtjevu 2 naznačen time da, za katalizator iz koraka a) ili b), količina metala iz skupine VIB je u rasponu 5% do 40 masenih % oksida metala iz skupine VIB u odnosu na ukupnu masu katalizatora, količina metala iz skupine VIII je u rasponu 1% do 10 masenih % oksida metala iz skupine VIII u odnosu na ukupnu masu katalizatora, i količina fosfora je u rasponu 0.1% do 10 masenih % P>O5 u odnosu na ukupnu masu katalizatora.
It is furthermore preferred according to the present invention that the mobile communication technology is one out of the following: 
Postupak prema jednom od prethodnih zahtjeva, pri čemu je mobilna komunikacijska tehnologija jedna od slijedećih:
Compound for use according to claim 15, wherein the pain is selected from the group consisting of chronic pain, neuropathic pain, inflammatory pain, pain due to osteoarthritis, pain due to arthritis, pain due to rheumatoid arthritis, cancer pain, pain due to spinal cord injury, surgical pain, post-operative pain or acute pain. 
Spoj za uporabu prema zahtjevu 15, naznačen time da je bol odabrana iz skupine koja sadrži kroničnu bol, neuropatsku bol, upalnu bol, bol zbog osteoartritisa, bol zbog artritisa, bol zbog reumatoidnog artritisa, bol zbog karcinoma, bol zbog ozljede leđne moždine, operativnu bol, postoperativnu bol ili akutnu bol.
The compound according to Claim 3, wherein the bicyclic ring which is formed by ring A fused with the adjacent ring is 4,5,6,7-tetrahydroindazol-5-yl. 
[image] pri čemu biciklički prsten koji je načinjen od prstena A spojenog sa susjednim prstenom je 4,5,6,7-tetrahidroindazol-5-il; predstavlja ciklopropil;
The process according to claim 9, wherein the solvent or the mixture of solvents is isopropyl acetate. 
Postupak sukladno patentnom zahtjevu 9, naznačen time što otapalo ili smjesa otapala je izopropil acetat.
Another important constituent of the composite material is the polymerizable resin base. 
Sljedeći važan konstituent kompozitnog materijala je baza za smolu koja polimerizira,
The dredge tooth in accordance with claim 1, characterized by an opening (101) for receiving a lock (16) to secure the dredge tooth (14) to the base (12). 
Potrošni element u skladu s patentnim zahtjevom 1, naznačen time što stražnja stijenka (105) određuje nosivu površinu za bravu (16).
The method according to claim 2, wherein the disease is essential thrombocythemia (ET). 
Spoj ili sol za upotrebu prema patentnom zahtjevu 16, naznačen time da je navedeni mijeloproliferativni poremećaj esencijalna trombocitemija (ET).
providing a glycosylated human SAP polypeptide, wherein the glycosylated human SAP polypeptide comprises an N-linked oligosaccharide chain; and ii) enzymatically or chemically altering the N-linked oligosaccharide chain of the human SAP polypeptide to produce a modified glycosylated human SAP polypeptide, wherein at least one branch of the oligosaccharide chain terminates with a a2,3-linked sialic acid moiety. 
pribavljanje glikoliziranog humanog SAP polipeptida, pri čemu glikozilirani humani SAP polipeptid sadržava oligosaharidni lanac vezan na N; i ii) enzimsku ili kemijsku promjenu oligosaharidnog lanca vezanog na N humanog SAP polipeptida kako bi se dobio modificirani glikozilirani humani SAP polipeptid, pri čemu barem jedna grana oligosaharidnog lanca završava kiselinskom skupinom sijalične kiseline vezanim na a2,3.
or their pharmaceutically acceptable salts, hydrates, or hydrated salts, or the polymorphic crystalline structures of these compounds or their optical isomers, racemates, diastereomers or enantiomers. 
O o kao i odgovarajući N-hidroksisukcinimidilni esteri, ili njihove farmaceutski prihvatljive soli, hidrati ili hidrati soli, ili polimorfne kristalne strukture tih spojeva ili njihovih optičkih izomera, racemata, dijastereoizomera ili enantiomera.
providing an oligosaccharide comprising a first reactive group, wherein the oligosaccharide is 
(a) osiguravanje oligosaharida koji sadrži prvi reaktivnu skupinu, pri čemu je oligosaharid "0gPQ HO o,
is a pharmaceutically acceptable cation; 
M je farmaceutski prikladan kation;
A structure according to claim 6, characterized in that the main structure (46) of the upright (24) has a substantially "omega"-shaped cross-section. 
Konstrukcija u skladu s patentnim zahtjevom 4, naznačena time, da glavna konstrukcija (46) stupića (24) ima u biti "omega"-oblikovani poprečni presjek.
transmitting a “leak” alert over the system network before ending the method; and 
• korak (13-7) za slanje upozorenja o curenju u mrežu sustava prije završavanja postupka.
three heavy chain polypeptide CDRs depicted in SEQ ID NOs: 4, 9, and 14, respectively, or in their conservative sequence variants, and three light chain polypeptide CDRs depicted in SEQ ID NOs: 27, 32, and 37, respectively, or in their conservative sequence variants; wherein the anti-VAP-1 antibody or a VAP-1 binding fragment thereof shows an improved serum concentration over time (AUC) profile and an extended elimination half-life over that of a chimeric anti-VAP-1 antibody, which in WO 03/093319 is designated as BTT-1002, of which the VH and VL are defined by the SEQ ID NO: 15 and 21, respectively. 
HR P20150615 T1 PATENTNI ZAHTJEVI Anti-VAP-1 protutijelo ili njegov vezni dio VAP-1, karakteriziran na način da je potpuno ljudski 1 sadrži polipeptid teškog lanca opisan slijedom identifikacijskog broja SEQ ID NO: 47 ili inačica njegovog nepromjenjivog slijeda, i polipeptid lakog lanca opisan u SEQ ID NO: 48 ili inačica njegovog nepromjenjivog slijeda; pri čemu anti-VAP-1 protutijelo ili njegov vezni dio VAP-1 pokazuje poboljšani profil koncentracije u serumu tijekom vremena (AUC) i produljeno poluvrijeme eliminacije u odnosu na kimerično anti-VAP-1 protutijelo nazvano BTT-1002.
The method of any one of 73-84, wherein said dermal micro organ comprises at least part of the cross-section of the dermis. 
Uporaba iz patentnog zahtjeva 8, naznačena time, da navedeni dermalni mikroorgan sadrži najmanje dio poprečnog presjeka dermisa.
Use of a compound of formula (I) or a physiologically acceptable solvate thereof as defined in claim 1 or claim 2, for the manufacture of a medicament for the treatment of inflammatory and/or allergic conditions. 
Upotreba spoja formule (1), ili njegovog fiziološki prihvatljivog solvata, u skladu s patentnim zahtjevom 1 ili patentnim zahtjevom 2, naznačena time što navedeni spoj je namijenjen proizvodnji medikamenta za liječenje upalnih i/ili alergijskih stanja.
hypromellose in a proportion comprised of between 0.3% and 1.0%; 
- < hipromelozu, u udjelu koji se kreće između 0,3% i 1,0%;
Phosphorylase a does not require AMP for activation, although addition of AMP can produce a 10-20% increase in activity (Oikonomakos et al., 1999) Protein Sci. 
Fosforilaza ne treba AMP za aktivaciju, iako dodavanje AMP može dovesti do 10-20% povećanja aktivnosti (Oikonomakos i suradnici, 1999) Protein Sci.
The system according to claim 14, wherein the sealing material is selected from the group consisting of fibers, paper, cotton, viscous paste, and foam. 
Sustav u skladu s bilo kojim od patentnih zahtjeva 15 do 17, u kojemu je materijal za brtvljenje (8) odabran iz skupine koja sadržava vlakna, papir, pamuk, viskoznu pastu, pjenu.
The compound of claim 1, wherein ring D is wherein, both of A1 and A2 are C or N; 
Spojevi prema patentnom zahtjevu 1, pri čemu prsten D je [image] i [image] pri čemu, oba od A1 i A2 su C ili N;
Method for the control of power ramp-rates minimizing energy storage requirements in intermittent power generation plants according to claim 1 characterized in that the maximum plant power, PMax(t), and/or the minimum plant power, PMin(t) are calculated through specific values of meteorological variables, such as wind speed, vw(t), and temperature, T(t), wherein the intermittent power generation plant is a wind turbine or wind farm. 
Metoda za kontrolu brzine napajanja koja minimizira zahtjeve za skladištenjem energije u povremenim postrojenjima za proizvodnju električne energije prema zahtjevu 1, naznačena time što se izračunavaju najveća snaga postrojenja, Pygx(t) i / ili minimalna snaga postrojenja, Pmin(t) putem specifičnih vrijednosti meteoroloških varijabli, poput brzine vjetra, v,(t) i temperatura, T(t), pri čemu je povremena elektrana za proizvodnju energije vjetrenjača ili vjetroolektrana.
Such a metal coating gives very good performances and allows to effectively lead any charges accumulating in the top coating down the substrate through which they are then lead to the ground. 
Takav metalni sloj ima vrlo dobre karakteristike i omogućuje učinkovito provođenje svih naboja akumuliranih u gornjem sloju u podlogu kroz koju se potom provode u zemlju.
The method of claim 9, wherein the ready to drink coffee beverage further comprises one or more whiteners selected from the group consisting of milk, cream, non dairy creamer, soymilk, rice milk, and coconut milk. 
Postupak u skladu s patentnim zahtjevom 9, naznačen time što instant kaveni napitak dodatno sadrži jedno ili više bjelila, koja se bira iz skupine koju čine mijeko, slatko vrhnje, umjetno vrhnje nemliječnog podrijetla, sojino mijeko, rižino mijeko, te kokosovo mijeko.
represents hydrogen or alkyl; and 
R> predstavlja vodik ili alkil;
The reaction mixture was maintained at room temperature, following the reaction by LCMS. On completion of the reaction, the reaction mixture was concentrated under vacuum to a solid, then taken up in 50% acetonitrile/water, filtered, and the residue washed with more acetonitrile/water. 
Reakcijska smjesa održavana je kod sobne temperature, pomoću LCMS sljeđena je reakcija, reakcijska smjesa koncentrirana je pod vakuumom do krutog, nakon toga prenesena je u 50% acetonitril/voda, filtrirana, a ostatak je ispran sa više acetonitril/voda.
The method of embodiment 881, wherein a single or divided dose of 140 mg of said antibody is administered at time "0" (the first administration), at one week post time "0" (week one), and then administered every two weeks to patients weighing less than or approximately equal to 100 kg, and wherein a single or divided dose of 280 mg of said antibody is administered at time "0" (the first administration), at one week post time "0" (week one), and then administered every two weeks to patients weighing greater than 100 kg. 
Farmaceutska formulacija za upotrebu prema zahtjevu 7, naznačena time da se doza od 140 mg navedenog protutijela daje pacijentima koji imaju tjelesnu masu koja je manja od ili približno jednaka 100 kg, te da se doza od 210 mg navedenog protutijela daje pacijentima koji imaju tjelesnu masu koja je veća od 100 kg.
A process according to claim 7, wherein N-(3-cyano-4-methyl-1 H -indol-7-yl)-3-cyanobenzenesulfonamide is heated and dissolved in a solvent and then crystallized by gradual cooling. 
Postupak u skladu s patentnim zahtjevom 7, naznačen time, da se N-(3-cijano-4-metil-1H-indol-7-il)-3-cijanobenzen-sulfonamid zagrijava i otapa u otapalu i zatim kristalizira postupnim hlađenjem.
an antibody comprising a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 215 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 220; 
(9) protutijelo koje sadržava varijabilnu regiju teškog lanca koja sadržava aminokiselinski slijed SEQ ID NO: 215 (H92) 1 varijabilnu regiju lakog lanca koja sadržava aminokiselinski slijed SEQ ID NO: 220 (L17) (H92L17);
As used with reference to the utilities described herein, the term “treating” or “treatment” encompasses prevention, partial alleviation, or cure of the disease or disorder. 
Kao što se upotrebljava kod upućivanja na primjene koje su ovdje opisane, termin "obrada" ili "liječenje" obuhvaća prevenciju, djelomično ublaživanje ili liječenje bolesti ili poremećaja.
A is a nitrogen containing group which may be selected from: 
A je skupina koja sadrži dušik koja je odabrana od: